Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy.
Pretreatment Neutrophil-to-Lymphocyte Ratio and Lactate Dehydrogenase Predict the Prognosis of Metastatic Cervical Cancer Treated with Combination Immunotherapy.
复制标题
治疗前中性粒细胞与淋巴细胞的比率和乳酸脱氢酶可预测联合免疫疗法治疗的转移性宫颈癌的预后
DOI：
10.1155/2022/1828473
复制
发表时间：
2022
影响因子：
--
通讯作者：
Jiang, Yao
中科院分区：
文献类型：
--
作者：
Cheng, Mingxia;Li, Guiling;Liu, Zhongan;Yang, Qin;Jiang, Yao
背景 免疫检查点抑制剂极大地改变了转移性宫颈癌的治疗模式。尽管如此，只有一部分患者获得了持久的缓解。因此，探索免疫治疗反应的预测生物标志物至关重要。本研究旨在评估血液学参数对接受联合免疫治疗的转移性宫颈癌患者的预测和预后价值。方法回顾性分析2019年6月至2021年4月接受联合免疫治疗的转移性宫颈癌患者的临床资料。进行受试者工作特征曲线分析以确定连续变量的截止值，并进行二元逻辑分析以比较组间的治疗反应。 Kaplan-Meier 方法用于生存分析。使用 Cox 比例风险回归模型来确定与无进展生存期 (PFS) 相关的因素。结果本研究共纳入 70 名患者。中性粒细胞与淋巴细胞比率（NLR）和乳酸脱氢酶（LDH）的截止值分别为5.33和195.00U/L。治疗前高 NLR（≥5.33）与客观缓解率降低相关（53.19% vs. 78.26%，p = 0.048）。生存分析显示，高治疗前 NLR（风险比 [HR] = 2.401，95% 置信区间 [CI]：1.151–5.009，p = 0.020）和 LDH 水平（HR = 1.987，95% CI：1.029–3.835，p = 0.041）是与短 PFS 相关的独立预后因素。结论 我们的研究表明，治疗前较高的 NLR 和 LDH 值与接受联合免疫治疗的转移性宫颈癌患者的不良生存率独立相关。治疗前的 NLR 和 LDH 值可以作为潜在的生物标志物，有助于选择从联合免疫治疗中受益的患者。有必要进行进一步的前瞻性研究来调查 NLR 和 LDH 的预后价值。试验注册号：UHCT22008。
Background Immune checkpoint inhibitors have considerably changed the treatment paradigm for metastatic cervical cancer; nonetheless, only a proportion of patients achieve a durable response. Therefore, exploring the predictive biomarkers of immunotherapy response is of crucial importance. This study aimed to evaluate the predictive and prognostic value of hematological parameters in patients with metastatic cervical cancer treated with combination immunotherapy. Methods Clinical data of patients with metastatic cervical cancer treated with combination immunotherapy between June 2019 and April 2021 were retrospectively analyzed. Receiver operating characteristic curve analysis was performed to determine the cut-off values of continuous variables, and binary logistic analysis was conducted to compare the treatment response between groups. The Kaplan–Meier method was applied for survival analysis. A Cox proportional hazards regression model was used to identify factors associated with progression-free survival (PFS). Results Seventy patients were included in this study. The cut-off values for the neutrophil-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH) were 5.33 and 195.00 U/L, respectively. High pretreatment NLR (≥5.33) was correlated with decreased objective response rate (53.19% vs. 78.26%, p = 0.048). The survival analysis revealed that high pretreatment NLR (hazard ratio [HR] = 2.401, 95% confidence interval [CI]: 1.151–5.009, p = 0.020) and LDH level (HR = 1.987, 95% CI: 1.029–3.835, p = 0.041) were independent prognostic factors associated with short PFS. Conclusions Our study suggested that high pretreatment NLR and LDH values were independently correlated with poor survival in patients with metastatic cervical cancer treated with combination immunotherapy. Pretreatment NLR and LDH values could serve as potential biomarkers that may aid in the selection of patients who would benefit from combination immunotherapy. Further prospective studies investigating the prognostic value of NLR and LDH are warranted. Trial registration number: UHCT22008.
登录
查看更多内容
影响因子：
28.4
作者：
Mezquita, Laura;Auclin, Edouard;Besse, Benjamin
通讯作者：
Besse, Benjamin
影响因子：
45.3
作者：
Armstrong, Andrew J.;George, Daniel J.;Halabi, Susan
通讯作者：
Halabi, Susan
影响因子：
5.3
作者：
Bagley, Stephen J.;Kothari, Shawn;Langer, Corey J.
通讯作者：
Langer, Corey J.
影响因子：
5.8
作者：
Criscitiello, Carmen;Marra, Antonio;Curigliano, Giuseppe
通讯作者：
Curigliano, Giuseppe
影响因子：
7.5
作者：
Huang, Richard S. P.;Haberberger, James;Lin, Douglas, I
通讯作者：
Lin, Douglas, I